| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Levonorgestrel (Norgestrel, Microval, Postinor, Mirena, Plan B) is a female hormone that can prevent ovulation and has been used in many birth control pills. Levonorgestrel is a synthetic progestin that binds to progesterone and androgen receptors/AR but not the estrogen receptor/ER. It induces apoptosis in ovarian epithelium cells. Levonorgestrel suppresses the stimulation of progesterone secretion induced by oLH, dibutyryl-cAMP and Pregnenolone in rats luteal cells. Levonorgestrel also inhibits constrictions evoked by either a high potassium (K(+)) solution or phorbol myristate acetate (PMA) in the absence and presence of extracellular calcium (Ca(2+)). Levonorgestrel is useful within 120 hours as emergency birth control. It becomes less effective the longer after sex and only works before pregnancy has occurred. It is also combined with an estrogen to make combined oral birth control pill.
| ln Vitro |
Levonorgestrel (5-25 mg/mL; 72 h) has the concentration-dependent ability to suppress cell growth and increase apoptosis in uterine leiomyoma cells [1]. Levonorgestrel (0.1-100 μM; 4 h) can decrease the generation of progesterone at high concentrations (100 μM) in luteal cells, while it has no effect at low doses (0-10 μM) [2].
|
|---|---|
| ln Vivo |
In Sprague–Dawley rats, levonorgestrel (0.005-0.15 mg/kg; once every two days for three weeks) decreases bone turnover, inhibits bone resorption, and raises bone mineral content [3]. Apodemus agrarius mice can successfully avoid pregnancy when levonorgestrel (1 mg/kg; gavage; once daily for three consecutive days) is combined with ethinyl estradiol [4].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: Uterine leiomyoma cells Tested Concentrations: 5 mg/mL; 10mg/mL; 20 mg/mL Incubation Duration: Experimental Results: Inhibited Bcl-2 and survivin expression at high concentrations (10 mg/mL and 20 mg /mL). Dramatically increased the phosphorylation of P38 phosphorylation and increased Caspase-3 expression at high concentrations (10 mg/mL and 20 mg/mL). |
| Animal Protocol |
Animal/Disease Models: Apodemus agrarius model[4]
Doses: 1 mg/kg Route of Administration: intragastric (po) administration (ig), one time/day for three days Experimental Results: Damaged the sperm ducts, decreased sperm production in combination with quinestrol. decreased population density in the field in combination with quinestrol. |
| References |
[1]. Xu Qing, et al. Levonorgestrel inhibits proliferation and induces apoptosis in uterine leiomyoma cells. Contraception vol. 82,3 (2010): 301-8.
[2]. Tellería C M, et al. Levonorgestrel inhibits luteinizing hormone-stimulated progesterone production in rat luteal cells. The Journal of steroid biochemistry and molecular biology vol. 50,3-4 (1994): 161-6. [3]. Liao Er-yuan, et al. Effects of different nylestriol/levonorgestrel dosages on bone metabolism in female Sprague-Dawley rats with retinoic acid-induced osteoporosis. Endocrine research vol. 29,1 (2003): 23-42. [4]. Chen Xiaoning, et al. Anti-fertility effect of levonorgestrel and/or quinestrol on striped field mouse (Apodemus agrarius): evidence from both laboratory and field experiments. Integrative zoology vol. 17,6 (2022): 1041-1052. [5]. Meng C-X, et al. Effects of oral and vaginal administration of levonorgestrel emergency contraception on markers of endometrial receptivity. Human reproduction (Oxford, England) vol. 25,4 (2010): 874-83. |
| Molecular Formula |
C21H28O2
|
|
|---|---|---|
| Molecular Weight |
312.45
|
|
| CAS # |
797-63-7
|
|
| Related CAS # |
Dydrogesterone;152-62-5;Levonorgestrel-d8;Norgestrel-d6;2376035-98-0
|
|
| SMILES |
O([H])[C@@]1(C#C[H])C([H])([H])C([H])([H])[C@@]2([H])[C@]3([H])C([H])([H])C([H])([H])C4=C([H])C(C([H])([H])C([H])([H])[C@]4([H])[C@@]3([H])C([H])([H])C([H])([H])[C@@]21C([H])([H])C([H])([H])[H])=O
|
|
| InChi Key |
WWYNJERNGUHSAO-XUDSTZEESA-N
|
|
| InChi Code |
InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1
|
|
| Chemical Name |
(8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2005 mL | 16.0026 mL | 32.0051 mL | |
| 5 mM | 0.6401 mL | 3.2005 mL | 6.4010 mL | |
| 10 mM | 0.3201 mL | 1.6003 mL | 3.2005 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA